Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment

CardioRenal Medicine

Volumn 5, Issue 4, 2015, Pages 254-266

  Di Lullo, Luca ^a   Gorini, Antonio ^a   Russo, Domenico ^b   Santoboni, Alberto ^a   Ronco, Claudio ^c  

^a Ospedale Parodi Delfino   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Chronic kidney disease; Echocardiography; Left ventricular hypertrophy; Type 4 cardiorenal syndrome

Indexed keywords

ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOLOGIST; CARDIORENAL SYNDROME; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; END STAGE RENAL DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FIBROSIS; MEDICAL DECISION MAKING; NEPHROLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY HYPERPARATHYROIDISM; SUDDEN CARDIAC DEATH; THREE DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 84945926172     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000435838     Document Type: Article

References (85)

1. Ronco C: The cardiorenal syndrome: basis and common ground for a multidisciplinary patient-oriented therapy. Cardiorenal Med 2011; 1: 3-4.
2. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J; ADHERE Scientific Advisory Committee and Investigators: High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J Card Fail 2007; 13: 422-430.
3. Garg AX, Clark WF, Haynes RB, House AA: Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61: 1486-1494.
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031.
5. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-890.
6. US Renal Data System: USRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
7. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006; 17: 2034-2047.
8. US Renal Data System: USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
10. Shastri S, Sarnak MJ: Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis 2010; 56: 399-417.
11. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, Brown WW, Burrows NR, Jurkovitz CT, McFarlane SI, Norris KC, Shlipak M, Whaley-Connell AT, Chen SC, Bakris GL, McCullough PA: Prevalence of CKD and comorbid illness in elderly patients in the united states: results from the kidney early evaluation program (KEEP). Am J Kidney Dis 2010; 55(3 suppl 2):S23-S33.
12. Bansal N, Keane M, Delafontaine P, Dries D, Foster E, Gadegbeku CA, Go AS, Hamm LL, Kusek JW, Ojo AO, Rahman M, Tao K, Wright JT, Xie D, Hsu CY; CRIC Study Investigators: A longitudinal study of left ventricular function and structure from CKD to ESRD: The CRIC study. Clin J Am Soc Nephrol 2013; 8: 355-362.
13. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J: Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2007; 18: 1307-1315.
14. Di Lullo L, Floccari F, Polito P: Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clin Pract 2011; 118:c258-c262.
15. Foley RN, Curtis BM, Randell EW, Parfrey PS: Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 2010; 5: 805-813.
16. Parikh SV, de Lemos JA: Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci 2006; 332: 186-197.
17. Ritz E, Wanner C: The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 2008; 3: 920-929.
18. Gross ML, Ritz E: Hypertrophy and fibrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Semin Dial 2008; 21: 308-318.
19. Ritz E: Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int 2009; 75: 771-773.
20. Mominadam S, et al: Interdialytic blood pressure obtained by ambulatory blood pressure measurement and left ventricular structure in hypertensive hemodialysis patients. Hemodial Int 2008; 12: 322-327.
21. Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R: Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol 2007; 27: 159-163.
22. Xu X, Hu X, Zhang P, Zhao L, Wessale JL, Bache RJ, Chen Y: Xantine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail 2008; 14: 746-753.
23. Hsu S, Nagayama T, Koitabashi N, Zhang M, Zhou L et al: Phosphodiesterase-5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res 2009; 81: 301-309.
24. Martin LC, Franco RJ, Gavras I, Matsubara BB, Garcia S, Caramori JT, Barretti BB, Balbi AR, Barsanti R, Padovani C, Gavras H: Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens 2004; 17: 1163-1169.
25. McRae JM, Levin A, Belenkie I: The cardiovascular effects of arteriovenous fistulas in chronic kidney disease. A cause for concern? Semin Dial 2006; 19: 349-352.
26. Nishida K, Kyoi S, Yamaguchi O, Sadoshima J, Otsu K: The role of autophagy in the heart. Cell Death Differ 2009; 16: 31-38.
27. Dorm GW 2nd: Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodeling. Cardiovasc Res 2009; 81: 465-473.
28. Zoccali C, Benedetto FA, Tripepi G, Mallamaci F: Cardiac consequences of hypertension in hemodialysis patients. Semin Dial 2004; 17: 299-303.
29. Sakurabayashi T, Miyazaki S, Yuasa Y, Sakai S, Suzuki M, Takahashi S, Hirasawa Y: L-Carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ J 2008; 72: 926-931.
30. Strozecki P, et al: Parathormon, calcium, phosphorus and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail 2001; 23: 115-126.
31. Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, Gross ML: Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calciomimetic. Lab Invest 2009; 89: 520-530.
32. Oberleithner H, Riethmuller C, Schillers H, Mac Gregor GA, de Wardener HE, Hausberg M: Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA 2007; 104: 16281-16286.
33. De Paula FM, Peixoto AJ, Pinto LV, Dorigo D, Patricio PJ, Santos SF: Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int 2004; 66: 1232-1238.
34. Moe S, Drueke T, Cunningham J: Definition, evaluation and classification of renal osteodistrophy: A position statement from Kidney Disease Improving Global Outcome (KDIGO). Kidney Int 2006; 69: 1945-1953.
35. Moe S, Drueke TB, Block A, et al: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 113:S1-S130.
36. Burhiya R, Li S, Chen S, Mc Cullough PA, Bakris GL: Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009; 53:S3-S10.
37. Evenepoel P, Meijers B, Viaene L, et al: Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 1268-1276.
38. Isakova T, Wahl P, Vargas GS: Fibroblast growth factor-23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
39. Faul C, Amaral AP, Oskouei B, et al: FGF23 induces left ventricular hyperthrophy. J Clin Invest 2011; 12: 4393-4408.
40. Gutierrez OM, Mannstadt M, Isakova T, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
41. Isakova T, Xie H, Yang W: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
42. Liu X, Xie R, Liu S: Rat parathyroid hormone 1-34 signals through the MEK/ERK pathway to induce cardiac hypertrophy. J Int Med Res 2008; 36: 942-950.
43. Moon KH, Song IS, Yang WS, Shin YT, Kim SB, Song JK, Park JS: Hypoalbuminemia as a risk factor for progressive left-ventricular hypertrophy in hemodialysis patients. Am J Nephrol 2000; 20: 396-401.
44. Chmielewski M, Carrero JJ, Stenvinkel P, Lindholm B: Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Curr Opin Lipidol 2009; 20: 3-9.
45. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
46. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K: Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1144-1151.
47. Testa A, Mallamaci F, Benedetto F, Pisano A, Tripepi G, Malatino L, Thadhani R, Zoccali C: Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. J Bone Miner Res 2010; 25: 313-319.
48. El-Shehaby AM, El-Khatib MM, Marzouk S, Battah AA: Relationship of BsmI polymorphism of vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients. Scand J Clin Lab Invest 2013; 73: 75-81.
49. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 2012; 307: 674-684.
50. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS: Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65: 1492-1498.
51. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767.
52. Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C: Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2008; 74: 1461-1467.
53. Aoki J, Ikari Y, Nakajima H, Mori M, Sugimoto T, Hatori M, Tanimoto S, Amiya E, Hara K: Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 2005; 67: 333-340.
54. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G: Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005; 46: 320-327.
55. McMahon LP, Roger SD, Levin A: Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004; 15: 1640-1647.
56. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, Manns BJ: Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA 2007; 298: 1291-1299.
57. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11: 912-916.
58. Covic A, Mardare NG, Ardeleanu S, Prisada O, Gusbeth-Tatomir P, Goldsmith DJ: Serial echocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation. J Nephrol 2006; 19: 783-793.
59. Marchais SJ, Metivier F, Guerin AP, London GM: Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999; 14: 2178-2183.
60. Galetta F, Cupisti A, Franzoni F, Femia FR, Rossi M, Barsotti G, Santoro G: Left ventricular function and calcium phosphate plasma levels in uraemic patients. J Intern Med 2005; 258: 378-384.
61. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P: Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: A meta-analysis. Clin J Am Soc Nephrol 2009; 4: 755-762.
62. Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC: Epoetin alfa and darbepoetin alfa: Effects on ventricular hypertrophy in patients with chronic kidney disease. J Nephrol 2008; 21: 543-549.
63. Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI, Luno J: Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin 10 g/dl. Kidney Int 2005; 68: 788-795.
64. Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G: Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004; 97: 383-388.
65. Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlof B: Progressive hypertrophy regression with sustained pressure reduction in hypertension: The Losartan Intervention for Endpoint Reduction study. J Hypertens 2002; 20: 1445-1450.
66. Jula AM, Karanko HM: Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation 1994; 89: 1023-1031.
67. Charra B, Chazot C: Volume control, blood pressure and cardiovascular function. Lessons from hemodialysis treatment. Nephron Physiol 2003; 93: 94-101.
68. Achinger SG, Ayus JC: The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int 2005; 68:(suppl):S37-S42.
69. Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Kubo Y, Mahaffey KW, Goodman WG, Moe SM, Trotman ML, Abdalla S, Chertow GM, Herzog CA: Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. J Am Heart Assoc 2014; 3:e001363.
70. Ly J, Chan CT: Impact of augmenting dialysis frequency and duration on cardiovascular function. ASAIO J 2006; 52:e11-e14.
71. Fagugli RM, Pasini P, Pasticci F, Ciao G, Cicconi B, Buoncristiani U: Effects of short daily hemodialysis and extended standard hemodialysis on blood pressure and cardiac hypertrophy: A comparative study. J Nephrol 2006; 19: 77-83.
72. Weinreich T, De los Rios T, Gauly A, Passlick-Deetjen J: Effects of an increase in time vs frequency on cardiovascular parameters in chronic hemodialysis patients. Clin Nephrol 2006; 66: 433-439.
73. Kong CH, Farrington K: Determinants of left ventricular hypertrophy and its progression in high-flux haemodialysis. Blood Purif 2003; 21: 163-169.
74. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebocontrolled trial. J Am Coll Cardiol 2003; 41: 1438-1444.
75. Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A; INDEPENDENT Study Investigators: Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013; 62: 771-778.
76. Pewsner D, Juni P, Egger M, Battaglia M, Sundstrom J, Bachmann LM: Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ 2007; 335: 711.
77. Stewart GA, Foster J, Cowan M, Rooney E, McDonagh T, Dargie HJ, Rodger RS, Jardine AG: Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999; 56: 2248-2253.
78. Mark PB, Patel RK, Jardine AG: Are we overestimating left ventricular abnormalities in end-stage renal disease? Nephrol Dial Transplant 2007; 22: 1815-1819.
79. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774.
80. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in endstage renal disease. Kidney Int 1989; 36: 286-290.
81. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277-1285.
82. Ritz E, Bommer J: Cardiovascular problems on hemodialysis: current deficits and potential improvement. Clin J Am Soc Nephrol 2009; 4:S71-S78.
83. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
84. Takeuchi M, Nishikage T, Mor-Avi V, Sugeng L, Weinert L, Nakai H, Salgo IS, Gerard O, Lang RM: Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. J Am Soc Echocardiogr 2008; 21: 1001-1005.
85. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R: Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 2009; 53: 1621-1628.